RT Journal Article SR Electronic T1 Endothelial sampling in situ enables genetic characterization of vein of Galen Malformation JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2023.12.01.23299300 DO 10.1101/2023.12.01.23299300 A1 Hale, Andrew T. A1 Liu, Shanrun A1 Huang, Fengyuan A1 Song, Yuwei A1 Crowley, Michael R. A1 Crossman, David K. A1 Caudill, Caroline A1 Smith, Anastasia A. A1 Chapman, Lindsey A1 Feldman, Michael J. A1 Saccomano, Benjamin W. A1 Rocque, Brandon G. A1 Rozzelle, Curtis J. A1 Blount, Jeffrey P. A1 Johnston, James M. A1 Chong, Zechen A1 Jones, Jesse G. YR 2023 UL http://medrxiv.org/content/early/2023/12/05/2023.12.01.23299300.abstract AB Background and Objectives Vein of Galen malformation (VOGM), the result of arteriovenous shunting between choroidal and/or subependymal arteries and the embryologic prosencephalic vein, is among the most severe cerebrovascular disorders of childhood. While endovascular treatment options have improved outcomes, morbidity and mortality remain high. We hypothesized that in situ analysis of the VOGM lesion using endoluminal tissue sampling (ETS) is feasible and may advance our understanding of VOGM genetics, pathogenesis, and maintenance.Methods We collected germline DNA (cheek swab) from patients and their families for genetic analysis. In situ VOGM ‘endothelial’ cells (EC), defined as CD31+ and CD45-, were obtained from coils via ETS during routine endovascular treatment. Autologous peripheral femoral ECs were also collected from the access sheath. Single-cell RNA sequencing (scRNA-seq) of both VOGM and peripheral ECs was performed to demonstrate feasibility to define the transcriptional architecture. Comparison was also made to a published normative cerebrovascular transcriptome atlas. A subset of VOGM ECs was reserved for future DNA sequencing to assess for somatic and second-hit mutations.Results Our cohort contains 6 patients who underwent 10 ETS procedures from arterial and/or venous access during routine VOGM treatment (aged 12 days to ∼6 years). No periprocedural complications attributable to ETS occurred. Six unique coil types were used. ETS captured 98 ± 88 (mean ± SD; range 17-256) experimental ‘endothelial’ cells (CD31+ and CD45-). There was no discernable correlation between cell yield and coil type or route of access. Single cell RNA sequencing demonstrated hierarchical clustering and unique cell populations within the VOGM EC compartment compared to peripheral EC controls when annotated using a publicly available cerebrovascular cell atlas.Conclusion ETS appears safe and may supplement investigations aimed at development of a molecular-genetic taxonomic classification scheme for VOGM. Moreover, results may eventually inform the selection of personalized pharmacologic or genetic therapies for VOGM and cerebrovascular disorders more broadly.Competing Interest StatementConflict of Interest: A.T.H. and J.G.J. received material support (i.e. coils) from Balt for the purposes of this study. Balt played no role in designing, collecting, interpreting, or reporting the data presented in this manuscript. This paper has been submitted for presentation consideration at the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) joint section for Pediatric Neurosurgery in Oklahoma City, OK (USA) in December 2023. Funding StatementDisclosure of Funding: The Aneurysm and AVM Foundation (TAAF), Joe Niekro Foundation (JNF), Robert J. Dempsy, MD Research Award from the American Association of Neurological Surgeons (AANS) and Congress of Neurological Surgeons (CNS) joint section for Cerebrovascular Neurosurgery, Kaul Pediatric Research Institute (KPRI) of Childrens of Alabama, and the Center for Clinical and Translational Sciences (CCTS) at University of Alabama at Birmingham provided funding for this study. A.T.H. and Z.C. are supported by the National Institutes of Health (R21 NS135321). Z.C. also received support from the National Institutes of Health (R35 GM138212).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee/IRB of University of Alabama at Birmingham gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.